Nanotherapeutics

Your Biopharmaceutical Development and Manufacturing Partner

Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease

Business Wire - December 2009

Nanotherapeutics announced that it has acquired two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 from EPIX Pharmaceuticals, Inc. Ramoplanin is an oral antibiotic for the treatment of Clostridium difficile-associated disease (CDAD). PRX-3140 is an orally-bioavailable Alzheimer's treatment.

Full Article

Copyright 2016 NANOTHERAPEUTICS, INC.  All rights reserved.